Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.51 USD
Change Today -0.0085 / -1.64%
Volume 1.0K
BNIKF On Other Exchanges
As of 12:27 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

benitec biopharma ltd (BNIKF) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/8/14 - $3.77
52 Week Low
10/31/14 - $0.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

benitec biopharma ltd (BNIKF) Related Businessweek News

No Related Businessweek News Found

benitec biopharma ltd (BNIKF) Details

Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company’s ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington’s disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.

13 Employees
Last Reported Date: 08/22/14
Founded in 1997

benitec biopharma ltd (BNIKF) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: A$450.0K
Chief Financial Officer and Company Secretary
Total Annual Compensation: A$267.4K
Chief Business Officer
Total Annual Compensation: A$302.0K
Founding Scientist and Head of Discovery
Total Annual Compensation: A$225.0K
Chief Scientific Officer
Total Annual Compensation: A$305.1K
Compensation as of Fiscal Year 2014.

benitec biopharma ltd (BNIKF) Key Developments

Benitec Biopharma Announces Collaboration with Reneuron

Benitec Biopharma announced the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with ReNeuron. The program aims to utilise Benitec's ddRNAi technology to address serious diseases using derived exosomes as delivery agents. Benitec and ReNeuron have completed a series of in vitro experiments that demonstrate that stem cells transduced with ddRNAi-expression constructs produce exosomes that are effective at delivering expressed shRNAs to target (cancer) cells and to knock down a specific gene in those cells. The data also indicated that ReNeuron's stem cells could be more effective than mesenchymal stem cells for this purpose. Whilst preliminary, these results could open the potential for both companies' platform technologies to be extended into a wide range of new therapeutic applications.

Benitec Biopharma Limited Presents at BIO International Convention 2015, Jun-16-2015 02:45 PM

Benitec Biopharma Limited Presents at BIO International Convention 2015, Jun-16-2015 02:45 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Carl S. Stubbings, Chief Business Officer.

Benitec Biopharma Doses Fifth Patient and Initiates Additional Trial Site For Hepatitis C Trial

Benitec Biopharma advised that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has been dosed at the Duke Clinical Research Unit. The fifth patient is the third and final patient to be dosed in Cohort 2. The three patients in Cohort 2 received a dose of TT-034 of 1.25 x 10^11 vg/kg, a concentration that is a half log higher than the doses administered in Cohort 1. In line with the trial's primary endpoint of safety, this dose level is still below the concentration expected to inhibit HCV viral replication and data from the second dosing cohort is therefore expected to serve primarily as a further safety assessment. As with previous patients, the newly dosed patient will be monitored for six weeks and this data will then be reviewed by the Data Safety Monitoring Board (DSMB). Benitec is currently screening patients for inclusion in cohort 3 in anticipation of the DSMB's review. Benitec has now initiated a third site, the Texas Liver Institute in San Antonio, Texas, and they have started to pre-screen patients for the TT-034 trial. Following completion of the first two patient cohorts and initiation of a third trial site, Benitec will now move to conventional clinical trial reporting for cohorts 3 through to 5 of the dose escalation study.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNIKF:US $0.51 USD -0.0085

BNIKF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $1.68 USD +0.02
Marina Biotech Inc $0.47 USD +0.0348
Regulus Therapeutics Inc $10.79 USD +0.68
Silence Therapeutics PLC 304.00 GBp +9.00
View Industry Companies

Industry Analysis


Industry Average

Valuation BNIKF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 42.8x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 28.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BENITEC BIOPHARMA LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at